血清中人附睾上皮分泌蛋白4的测定与卵巢上皮性肿瘤患者临床病理特征的关系

为探讨卵巢上皮性肿瘤患者血清人附睾上皮分泌蛋白4（HE4）水平的变化,以及与临床病理特征的关系,采用酶联免疫吸附试验（ELISA）检测21例良性卵巢上皮肿瘤患者、12例交界性卵巢上皮肿瘤患者和49例卵巢癌患者血清HE4水平,并分析其水平与临床病理特征的关系。卵巢癌组血清HE4水平（中位数123.00pmol/L）明显高于交界性卵巢上皮肿瘤组（中位数41.20pmol/L）和良性卵巢上皮肿瘤组（中位数32.80pmol/L）;血清HE4水平与卵巢上皮性癌患者是否绝经、年龄及有无淋巴结转移无关（P〉0.05）,而与患者的临床FIGO分期（Ⅰ＋Ⅱ、Ⅲ＋Ⅳ）、病理组织学类型及有无腹水有关（P〈0.05）,浆液性癌（中位数198.50pmol/L）和子宫内膜样癌患者的血清HE4水平（中位数139.25pmol/L）明显高于黏液性癌患者（中位数30.95pmol/L）（U值分别为17.00和2.00,P〈0.01）。血清HE4水平与卵巢上皮性癌临床病理特征密切相关,并有望成为卵巢上皮性肿瘤恶变的标志物。

Relationship Between the Serum Human Epididymis Secretory Protein 4 and Clinical Pathological Features in Patients with Epithelial Ovarian Cancer

To investigate the changes of serum human epididymis secretory protein 4（HE4） and its relationship with clinical pathological features in patients with epithelial ovarian neoplasm,the serum HE4 level in 21 patients with benign ovarian tumor,12 patients with borderline ovarian tumor and 49 patients with malignant epithelial ovarian neoplasm were detected by ELISA.The results showed that median serum levels of HE4 in the epithelial ovarian cancer group（123.00 pmol/L） were significantly higher than that of borderline ovarian tumors group（41.20 pmol/L） and benign ovarian tumors group（32.80 pmol/L）.The serum levels of HE4 in epithelial ovarian carcinoma had no significant correlation with menopause,age and lymph node metastasis（P0.05）.The serum level of HE4 was related with pathological stage,histological category and ascites in epithelial ovarian carcinoma（P0.05）.The median serum level of HE4 in serous ovarian carcinoma（198.50pmol/L） and endometrioid carcinoma（139.25pmol/L） were significantly higher than that in mucinous ovarian carcinoma（30.95 pmol/L）.The results suggest that the serum level of HE4 play an important role in clinical pathological features of epithelial ovarian carcinoma and may be considered as a marker reflecting tumor malignant behavior.